Acuta Capital Partners LLC Makes New Investment in Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

Acuta Capital Partners LLC purchased a new stake in Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 740,000 shares of the biopharmaceutical company's stock, valued at approximately $755,000. Acuta Capital Partners LLC owned approximately 0.35% of Sangamo Therapeutics at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in SGMO. Geode Capital Management LLC grew its stake in shares of Sangamo Therapeutics by 3.4% in the 4th quarter. Geode Capital Management LLC now owns 2,211,849 shares of the biopharmaceutical company's stock valued at $2,257,000 after buying an additional 73,540 shares during the period. Schonfeld Strategic Advisors LLC acquired a new stake in Sangamo Therapeutics in the fourth quarter valued at approximately $1,744,000. Charles Schwab Investment Management Inc. increased its holdings in shares of Sangamo Therapeutics by 3.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,139,252 shares of the biopharmaceutical company's stock valued at $1,162,000 after acquiring an additional 35,926 shares in the last quarter. State Street Corp raised its position in shares of Sangamo Therapeutics by 28.0% during the third quarter. State Street Corp now owns 664,621 shares of the biopharmaceutical company's stock worth $576,000 after purchasing an additional 145,400 shares during the period. Finally, Boothbay Fund Management LLC bought a new position in shares of Sangamo Therapeutics in the 4th quarter worth $548,000. Institutional investors and hedge funds own 56.93% of the company's stock.

Sangamo Therapeutics Trading Down 15.0 %

Shares of SGMO stock traded down $0.11 during trading on Tuesday, hitting $0.61. The company's stock had a trading volume of 7,259,020 shares, compared to its average volume of 8,556,215. The business has a fifty day moving average of $0.80 and a 200-day moving average of $1.38. Sangamo Therapeutics, Inc. has a 52 week low of $0.30 and a 52 week high of $3.18. The company has a market cap of $140.27 million, a PE ratio of -0.82 and a beta of 1.46.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last released its earnings results on Monday, March 17th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.02). Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%. The company had revenue of $7.55 million during the quarter, compared to analysts' expectations of $11.70 million. As a group, research analysts predict that Sangamo Therapeutics, Inc. will post -0.46 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on SGMO shares. Royal Bank of Canada restated a "sector perform" rating and set a $2.00 price objective on shares of Sangamo Therapeutics in a report on Tuesday, March 18th. Truist Financial dropped their price target on shares of Sangamo Therapeutics from $7.00 to $5.00 and set a "buy" rating on the stock in a research report on Thursday, January 23rd. Finally, HC Wainwright reissued a "buy" rating and set a $10.00 price objective on shares of Sangamo Therapeutics in a report on Monday, April 7th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $5.17.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.